Viridian Therapeutics, Inc.\DE - VRDN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Bellevue Group AG | 6.6% | 6,726,144 | View |
| May 15, 2026 | SCHEDULE 13G | Bellevue Asset Management AG | 6.6% | 6,726,144 | View |
| May 13, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
| May 08, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 5.3% | 5,417,660 | View |
| May 08, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 5.3% | 5,417,660 | View |
| May 08, 2026 | SCHEDULE 13G | David Kroin | 5.3% | 5,417,660 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kynam Capital Management, LP | 1.54% | 1,470,541 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 1.54% | 1,470,541 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Yue Tang | 1.54% | 1,470,541 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 2.65% | 2,524,833 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 2.65% | 2,524,833 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Kroin | 2.65% | 2,524,833 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.